The evolution of tyrosine‐kinase‐targeted cancer therapies
Future Prescriber · 2006
DOI: 10.1002/fps.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Mike Leahy.
Abstract (Originalsprache)
It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.
Zitieren
APA
Leahy, M. (2006). The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. https://doi.org/10.1002/fps.14
Vancouver
Leahy M. The evolution of tyrosine‐kinase‐targeted cancer therapies. Future Prescriber. 2006. doi:10.1002/fps.14
BibTeX
@article{Leahy2006,
author = {Leahy, Mike},
title = {The evolution of tyrosine‐kinase‐targeted cancer therapies},
journal = {Future Prescriber},
year = {2006},
doi = {10.1002/fps.14}
}
EUVIMED